Bio-Rad Laboratories, Inc. (BIO-B) AI Stock Analysis

Bio-Rad Laboratories, Inc. is a manufacturer and distributor of life science research and clinical diagnostic products across global markets including the United States, Europe, Asia, Canada, and Latin America. The company operates through two main segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets reagents, laboratory instruments, and apparatus used in research techniques, biopharmaceutical production, cellular biology, food safety, proteomics, and genomics. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical, reference, hospital, and transfusion laboratories.

Bio-Rad's annual revenue moved from $2.92B in FY2021 to $2.80B in FY2022, $2.67B in FY2023, and $2.57B in FY2024, before increasing 0.7% to $2.58B in FY2025. Gross margin shifted from 56.1% in FY2021 to 52.0% in FY2025, while operating margin fell from 17.1% to 10.5%. Net income has fluctuated significantly over the period, reporting $4.25B in FY2021, -$3.63B in FY2022, -$637.3M in FY2023, and -$1.84B in FY2024, before rebounding to $759.9M in FY2025 with an EPS of $27.92. Over the trailing twelve months, revenue was $2.59B with an operating margin of 11.2%. For the latest quarter ended June 30, 2026, quarterly revenue fell 0.1% year-over-year while quarterly earnings grew 18.7%.

As of June 30, 2026, Bio-Rad reported $1.62B in cash and short-term investments alongside total debt of $1.20B, resulting in a net cash position of $414.8M. Liquidity is supported by a current ratio of 3.14 and a debt-to-equity ratio of 0.17 against shareholders' equity of $7.17B. In FY2025, operating cash flow reached $532.2M and free cash flow was $374.6M. Capital allocation in FY2025 included $157.6M in capital expenditures and $295.5M in share buybacks, which contributed to a 10.4% reduction in shares over 5 years.

Bio-Rad trades at a trailing P/E of 46.2x and a forward P/E of 39.8x, which are higher than the US-listed Healthcare median of 24.6x and 17.3x, respectively. Its EV/EBITDA multiple of 17.3x is also above the peer median of 12.0x, though its price-to-sales multiple of 3.8x is slightly below the peer median of 4.1x. Over the past year, BIO-B gained 27.8%, outpacing the S&P 500 return of 17.5%. Over a 5-year period, however, the stock fell 50.7%, lagging the S&P 500 return of 86.0%.

For the current fiscal year ending December 31, 2026, consensus estimates project Bio-Rad's revenue to be $2.57B. In the following fiscal year, analysts forecast revenue to reach $2.62B, representing revenue growth of 2.1%. Bio-Rad has beaten earnings per share estimates in 3 of the last 4 quarters.

This page is an AI-written research summary of Bio-Rad Laboratories, Inc. (BIO-B). The text was generated on October 30, 2026 from Quotelinks data as of October 14, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BIO-B income statement, BIO-B balance sheet, BIO-B key metrics, BIO-B analyst forecast, BIO-B chart. See the BIO-B stock overview for the latest quote and news.